EPCAM epithelial cell adhesion molecule
ENSG00000119888 · protein coding · Open Targets profile
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. {ECO:0000269|PubMed:15195135, ECO:0000269|PubMed:15922867, ECO:0000269|PubMed:19785009, ECO:0000269|PubMed:20064925}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- Approved Drug, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.9756799936294556 (upper bound 1.274399995803833). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 5 registry trials, updated in the last three years, of the most advanced drugs against EPCAM (edrecolomab, oportuzumab monatox, IGN-101, tucotuzumab celmoleukin, adecatumumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Thomas ColacchioCancer and Leukemia Group B · 1 of 1 trials Phase 2+
- Raju ChelluriNational Cancer Institute (NCI) · 0 of 1 trials Phase 2+
Registry trials of edrecolomab, oportuzumab monatox, IGN-101, tucotuzumab celmoleukin, adecatumumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 4 of 5 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
3 trials of drugs against EPCAM were stopped early; 1 give no reason
Terminated, withdrawn and suspended interventional trials of edrecolomab, oportuzumab monatox, IGN-101, tucotuzumab celmoleukin, adecatumumab, citatuzumab bogatox, solitomab, ING-1, MOC31-PE, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 3 most recent of 3.
- withdrawn · 2017-08-18 · EMD Serono · Tucotuzumab celmoleukin (EMD 273066)“Th trial got cancelled and no subjects signed informed consent form (ICF); study design not appropriate any longer.”
- withdrawn · 2017-07-13 · James Ahlgren · edrecolomab“No recruitment”
- terminated · 2006-04-03 · Austrian Breast & Colorectal Cancer Study Group · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for EPCAM's drugs
For edrecolomab, oportuzumab monatox, IGN-101, tucotuzumab celmoleukin, adecatumumab, citatuzumab bogatox, solitomab, ING-1, MOC31-PE: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · EPCAM is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002797-PIP01-20 (oportuzumab monatox, Treatment of urothelial carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 12 Aug 2020Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-002797-PIP01-20, 2026-11-11
- EU orphan designation: no · No EU orphan designation names edrecolomab, oportuzumab monatox, ign-101, tucotuzumab celmoleukin, adecatumumab, citatuzumab bogatox, solitomab, ing-1, moc31-peRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · Oportuzumab monatox DLRC Pharma Services: application withdrawnRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Oportuzumab monatox DLRC Pharma Services, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of edrecolomab, oportuzumab monatox, ign-101, tucotuzumab celmoleukin, adecatumumab, citatuzumab bogatox, solitomab, ing-1, moc31-peRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: no · No interventional study of edrecolomab, oportuzumab monatox, ign-101, tucotuzumab celmoleukin, adecatumumab, citatuzumab bogatox, solitomab, ing-1, moc31-pe includes patients under 18Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 10 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.